



# Isolated Diastolic Hypertension in the IDACO Study: An Age-Stratified Analysis Using 24-Hour Ambulatory Blood Pressure Measurements

John W. McEvoy<sup>1</sup>, Wen-Yi Yang<sup>2</sup>, Lutgarde Thijs<sup>3</sup>, Zhen-Yu Zhang<sup>4</sup>, Jesus D. Melgarejo<sup>5</sup>, José Boggia<sup>6</sup>, Tine W. Hansen<sup>7</sup>, Kei Asayama<sup>8</sup>, Takayoshi Ohkubo<sup>9</sup>, Eamon Dolan, Katarzyna Stolarz-Skrzypek, Sofia Malyutina, Edoardo Casiglia<sup>10</sup>, Lars Lind<sup>11</sup>, Jan Filipovský<sup>12</sup>, Gladys E. Maestre<sup>13</sup>, Yan Li<sup>14</sup>, Ji-Guang Wang<sup>15</sup>, Yutaka Imai, Kalina Kawecka-Jaszcz, Edgardo Sandoya<sup>16</sup>, Krzysztof Narkiewicz<sup>17</sup>, Eoin O'Brien, Thomas Vanassche, Jan A. Staessen<sup>18</sup>; on behalf of the International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators

**ABSTRACT:** The prognostic implications of isolated diastolic hypertension (IDH), as defined by 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines, have not been tested using ambulatory blood pressure (BP) monitor thresholds (ie, 24-hour mean systolic BP <125 mmHg and diastolic BP ≥75 mmHg). We analyzed data from 11 135 participants in the IDACO (International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes). Using 24-hour mean ambulatory BP monitor values, we performed Cox regression testing independent associations of IDH with death or cardiovascular events. Analyses were conducted in the cohort overall, as well as after age stratification (<50 years versus ≥50 years). The median age at baseline was 54.7 years and 49% were female. Over a median follow-up of 13.8 years, 2836 participants died, and 2049 experienced a cardiovascular event. Overall, irrespective of age, IDH on 24-hour ambulatory BP monitor defined by 2017 American College of Cardiology/American Heart Association criteria was not significantly associated with death (hazard ratio, 0.95 [95% CI, 0.79–1.13]) or cardiovascular events (hazard ratio, 1.14 [95% CI, 0.94–1.40]), compared with normotension. However, among the subgroup <50 years old, IDH was associated with excess risk for cardiovascular events (2.87 [95% CI, 1.72–4.80]), with evidence for effect modification based on age (*P* interaction <0.001). In conclusion, using ambulatory BP monitor data, this study suggests that IDH defined by 2017 American College of Cardiology/American Heart Association criteria is not a risk factor for cardiovascular disease in adults aged 50 years or older but is a risk factor among younger adults. Thus, age is an important consideration in the clinical management of adults with IDH. (**Hypertension. 2021;78:1222–1231. DOI: 10.1161/HYPERTENSIONAHA.121.17766.**) • [Data Supplement](#)

**Key Words:** blood pressure ■ hypertension ■ morbidity ■ mortality ■ risk

**A**mbulatory blood pressure (BP) monitor (ABPM) recordings are considered superior to office BP recordings in quantifying cardiovascular disease risk.<sup>1,2</sup> This is because 24-hour ABPM provides multiple recordings and gives a more precise estimate of physiological BP levels during normal activity than once-off

measurements obtained in the clinic. In addition, ABPM recordings offer the opportunity to determine BP values during sleep, which have been shown to impart prognostic information.<sup>3</sup> Consequently, our understanding of a given BP phenotype is incomplete without data from 24-hour ABPM studies.

Correspondence to: Jan A. Staessen, MD, PhD, Research Institute Alliance for the Promotion of Preventive Medicine, Leopoldstraat 59, BE-2800 Mechelen, Belgium. Email [jan.staessen@appremed.org](mailto:jan.staessen@appremed.org)

This paper was sent to Daniel W. Jones, Guest Editor, for review by expert referees, editorial decision, and final disposition.

\*J.W. McEvoy and W.-Y. Yang are joint first authors.

The Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.121.17766>.

For Sources of Funding and Disclosures, see page 1230.

© 2021 The Authors. *Hypertension* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution Non-Commercial-NoDerivs](#) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

*Hypertension* is available at [www.ahajournals.org/journal/hyp](http://www.ahajournals.org/journal/hyp)

## Novelty and Significance

### What Is New?

- Using 24-hour ambulatory blood pressure monitor recordings, we found no statistically significant association between isolated diastolic hypertension (IDH) by 2017 American College of Cardiology (ACC)/American Heart Association (AHA) criteria and increased risk for outcomes in the IDACO (International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes) cohort overall.
- By contrast, when the cohort was stratified by age, risk for cardiovascular events was higher among persons younger than 50 years who had IDH by 2017 ACC/AHA criteria; but was not increased among older adults with IDH.

### What Is Relevant?

- Our data indicate that IDH by the 2017 ACC/AHA definition is not benign for adults younger than 50 years. These 24-hour ambulatory blood pressure monitor data help to settle an open question raised in prior registries using less rigorous recording of blood pressure, which indicated that age is an important consideration in the management of patients with IDH.

### Summary

These 24-hour ambulatory blood pressure monitor data confirm prior reports that IDH by the 2017 ACC/AHA definition is not associated with events in adults overall, irrespective of their age. Our IDACO data also confirm the known association between IDH by the 2018 European Society of Cardiology definition and events. As such, the 2018 European Society of Cardiology definition of IDH appears to be a stronger risk factor for cardiovascular events than the 2017 ACC/AHA definition. The null association between the 2017 ACC/AHA definition of IDH and events in adults over 50 years suggests that older adults with mild IDH do not need treatment as long as systolic BP is controlled. However, our data also indicate that the 2017 ACC/AHA definition of IDH is not completely benign for adults younger than 50 years. However, because young adults are at low absolute risk for events, future studies are needed to test whether pharmacological treatment of IDH in younger persons is efficacious and cost-effective. For now, lifestyle management is indicated among persons with IDH.

## Nonstandard Abbreviations and Acronyms

<b>ABPM</b>	ambulatory BP monitor
<b>ACC</b>	American College of Cardiology
<b>AHA</b>	American Heart Association
<b>BP</b>	blood pressure
<b>ICD</b>	<i>International Classification of Diseases</i>
<b>ICD-10</b>	<i>ICD, Tenth Revision</i>
<b>ICD-8</b>	<i>ICD, Eighth Revision</i>
<b>ICD-9</b>	<i>ICD, Ninth Revision</i>
<b>IDACO</b>	International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes
<b>IDH</b>	isolated diastolic hypertension
<b>ISH</b>	isolated systolic hypertension

One such phenotype, isolated diastolic hypertension (IDH), is less common than combined systolic-diastolic hypertension or isolated systolic hypertension (ISH).<sup>4</sup> However, depending on the definition applied, IDH can be seen in  $\geq 6\%$  of the adult population.<sup>5</sup> There are 2 definitions of IDH currently in widespread use; the 2018 European Society of Cardiology (ESC) guideline defines IDH as diastolic BP  $\geq 90$  mmHg and systolic BP  $< 140$  mmHg,<sup>6</sup> and the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guideline

defines IDH as diastolic BP  $\geq 80$  mmHg with a systolic BP  $< 130$  mmHg (note that both of these definitions assume office measurement of BP).<sup>7</sup>

There have been conflicting reports on the association of IDH with adverse cardiovascular outcomes, especially using the 2017 ACC/AHA definition.<sup>4,5,8-11</sup> Analyses suggesting a modest association between the ACC/AHA definition of IDH and events have come from large clinical registries that comprised of routine clinical recordings of BP, whereas analyses finding no association have analyzed BP values obtained under more rigorous research conditions.<sup>5,11,12</sup> In addition, one of the clinical registries reporting a modest association between the ACC/AHA definition of IDH and events demonstrated clear evidence for interaction on the basis of age, with a stronger association between IDH and events among young versus old participants.<sup>10</sup> By contrast, the null studies reported to date using standardized BP values obtained under rigorous research conditions have found no interaction by age.<sup>5,11</sup> To clarify this uncertainty, we studied cardiovascular outcomes in the IDACO (International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes) cohort among participants with IDH that was confirmed using 24-hour ABPM, focusing primarily on the 2017 ACC/AHA definition. Analyses were conducted in the IDACO sample overall and after stratification based on age.

## METHODS

The IDACO database is not publicly available; however, the authors declare that all supporting data are available within the article (and its [Data Supplement](#)).

### Study Population

Previous publications describe the IDACO database in more detail.<sup>3,13,14</sup> Participating population studies qualified for inclusion if office and ambulatory BP measures and cardiovascular risk factors were available at baseline and if follow-up included both fatal and nonfatal outcomes. Of 13 111 people included in the database, we excluded 1976, either because they were teenagers (<18 years) without events (n=493) or because they had an ambulatory BP recording with fewer than 6 daytime or 3 nighttime readings (n=1483).<sup>15</sup> Thus, the number of individuals analyzed was 11 135. We did not exclude persons on antihypertensive therapy in the main analysis, although we excluded them in a sensitivity analysis. The expanded methods section and Table S1 in the [Data Supplement](#) provide detailed information on the population sampling methods, timelines, and country of recruitment. All of the included studies received ethical approval from the responsible institutional review boards in their country of origin and all participants provided written informed consent.

### BP Measurement

Nurses or physicians obtained the conventional office BP clinical readings with standard auscultation using a mercury sphygmomanometer or with validated microphone or oscillometric automated BP measurement devices (see Expanded Methods in the [Data Supplement](#)). For ambulatory BP monitoring (Table S2), portable monitors were programmed to obtain ambulatory readings at 30-minute intervals throughout the whole day or at intervals of 15 to 30 minutes during daytime and at intervals ranging from 20 to 60 minutes during the nighttime.<sup>16</sup> Daytime readings ranged from 10 AM to 8 PM in European and South American countries and from 8 AM to 6 PM in Asian countries. The corresponding nighttime intervals ranged from midnight to 6 AM in European and South American countries and from 10 PM to 4 AM in Asian countries. The Expanded Methods section in the [Data Supplement](#) further describes the collection of questionnaire and biochemical data.

### Ascertainment of End Points

We ascertained vital status and the incidence of fatal and nonfatal events from the appropriate sources in each country.<sup>14</sup> All events were prespecified and coded according to the *International Classification of Diseases (ICD)*. The coprimary end points were total mortality and a composite cardiovascular event consisting of cardiovascular mortality (*ICD-8* [*ICD, Eighth Revision*], 390–448; *ICD-9* [*ICD, Ninth Revision*], 390.0–459.9; and *ICD-10* [*ICD, Tenth Revision*], I00–I79 and R96), coronary events (death from ischemic heart disease [*ICD-8*, 411–412; *ICD-9*, 411 and 414; and *ICD-10*, I20 and I24–I25], sudden death [*ICD-8*, 427.2 and 795; *ICD-9*, 427.5 and 798; and *ICD-10*, I46 and R96], nonfatal myocardial infarction [*ICD-8* or *ICD-9*, 410 and *ICD-10*, I21–I22], and coronary revascularization), stroke (*ICD-8* or *ICD-9*, 430–434 and 436; and *ICD-10*, I60–I64 and I67–I68, not including transient ischemic attack), and heart failure (*ICD-8*, 427.0, 427.1, 427.2, 428, 429, 519.1,

and 782.4, *ICD-9*, 429, and *ICD-10*, I50 and J81). Secondary outcomes included each of the individual outcomes included in the composite cardiovascular event end point. All outcomes were validated against hospital files or medical records held by participants' primary care physicians or specialists. In analyses of composite outcomes, we only considered the first event.

### Statistical Analysis

We used the Kolmogorov-Smirnov test for assessing the normality of distributions. For comparison of means and proportions, we applied the large-sample Z test and Fisher exact test, respectively. After stratification by cohort and sex, we interpolated missing values of body mass index and serum cholesterol levels from the regression slopes on age. In participants with unknown status of smoking, drinking, antihypertensive treatment, diabetes, or unknown history of cardiovascular disease, we set the indicator (dummy) variable to the cohort- and sex-specific mean of the codes (0, 1). Missing values were interpolated for body mass index (n=33), serum cholesterol level (n=806), smoking status (n=56), drinking status (n=805), antihypertensive treatment (n=16), diabetes (n=5), and history of cardiovascular disease (n=1).

Our analysis modeled 4 categorical exposures: normotension, IDH, ISH, and combined systolic-diastolic hypertension. Conversion of clinic BP thresholds to their respective ABPM equivalents was performed as recommended in 2017 ACC/AHA<sup>7</sup> and in 2018 ESC hypertension guidelines.<sup>17</sup> Specifically, the 24-hour systolic/diastolic ABPM thresholds for a diagnosis of IDH were 125/75 mmHg by AHA/ACC and 130/80 mmHg by ESC criteria. Similarly, the nighttime systolic/diastolic ABPM thresholds for a diagnosis of IDH were 110/65 mmHg by 2017 AHA/ACC and 120/70 mmHg by 2018 ESC criteria.

We compared the cumulative incidence of the primary and secondary outcomes by hypertension category, after adjusting for age and sex. In multivariable-adjusted Cox regression, we adjusted for cohort (random effect), sex, and baseline characteristics including age, body mass index, smoking and drinking status, serum cholesterol level, antihypertensive drug intake, diabetes, and history of cardiovascular disease. We checked the proportional hazards assumption by the Kolmogorov-type supremum test. We prespecified that all Cox regression analyses were conducted in the IDACO sample overall and after stratification on the basis of age (<50 years versus ≥50 years) and sex. In these stratified analyses, we tested for effect modification using multiplicative interaction terms.

Sensitivity analyses excluded individuals either on baseline antihypertensive medications or those with a baseline history of cardiovascular disease from the models. Finally, we also performed sensitivity analyses of our 4 main categorical exposures with further adjustment for either systolic BP or for diastolic BP as continuous covariables at baseline.

For the statistical analysis, we used SAS software, version 9.4. Statistical significance was a 2-tailed  $\alpha$  of ≤0.05.

## RESULTS

### Characteristics of Participants

The study sample analyzed (n=11 135) included 5494 women (49.3%) and consisted of 6929 White Europeans (62.2%), 1887 Asians (17.0%), and 2319 South

Americans (20.8%). The median age at baseline was 54.7 years. Study participants included 3022 (27.3%) smokers, 849 (7.6%) diabetics, and 1291 (11.6%) persons with a history of cardiovascular disease.

When applying the 2017 ACC/AHA hypertension criteria using 24-hour ambulatory BP thresholds, our sample comprised of 5418 (48.7%) participants with normal BP values, 1129 (10.1%) with BP values meeting criteria for IDH, 1325 (11.9%) with BP values meeting criteria for ISH, and 3263 (29.3%) with combined systolic-diastolic hypertension (Table 1). In comparison to those with normal BP values, persons with IDH by ACC/AHA criteria were numerically more likely to be South American and male. Otherwise, the baseline characteristics of normotensive participants and those with IDH appeared similar, as summarized in Table 1.

### Primary Analyses on the Whole Study Population


Median follow-up was 13.8 years (5th–95th percentile interval, 2.5–25.1 years). During 153 140 person-years

of follow-up, 2836 participants died (incidence rate of 18.5 per 1000 person-years) and 2049 experienced a composite cardiovascular event (13.4 per 1000 person-years), overall. When applying the 2017 ACC/AHA hypertension criteria, crude incidence rates (per 1000 person-years) for death and cardiovascular events were 12.0 and 7.8 among normotensive participants, 9.7 and 8.4 among those with IDH, 34.1 and 26.3 among those with ISH, and 27.2 and 23.5 among participants with combined hypertension. Age and sex-standardized cumulative incidence curves, for both outcomes and among each BP category, are presented in the Figure. Using the 2017 ACC/AHA criteria for IDH, there was no statistically significant crude excess in either mortality or cardiovascular events relative to the normal BP category. However, IDH according to 2018 ESC criteria was associated with an increased cumulative incidence of cardiovascular events (but not death). Irrespective of the guideline criteria applied, both ISH and combined systolic-diastolic hypertension were associated with an excess in death and cardiovascular events.

**Table 1. Baseline Characteristics of Participants by Hypertension Categories According to 24-Hour Ambulatory BP Thresholds in 2017 ACC/AHA Guidelines**

Characteristic	Normotensive	Isolated diastolic	Isolated systolic	Combined hypertension
N (%) of participants	5418	1129	1325	3263
European	3352 (61.9)	649 (57.5)	863 (65.1)	2065 (63.3)
Asian	999 (18.4)	140 (12.4)	209 (15.8)	539 (16.5)
South American	1067 (19.7)	340 (30.1)	253 (19.1)	659 (20.2)
Women	3239 (59.8)	485 (43.0)	599 (45.2)	1171 (35.9)
Current smoking	1430 (26.4)	331 (29.3)	317 (23.9)	944 (28.9)
Drinking alcohol	2422 (44.7)	569 (50.4)	755 (57.0)	2069 (63.4)
On antihypertensive treatment	671 (12.4)	152 (13.5)	407 (30.7)	1032 (31.6)
Diabetes	293 (5.4)	37 (3.3)	170 (12.8)	349 (10.7)
History of CVD	452 (8.3)	114 (10.1)	253 (19.1)	472 (14.5)
Mean (SD) characteristic				
Age, y	48.6 (16.0)	49.8 (12.6)	63.2 (14.6)	58.9 (12.7)
Body mass index, kg/m <sup>2</sup>	24.5 (4.1)	26 (4.2)	26.4 (4.7)	26.8 (4.3)
Serum total cholesterol, mmol/L	5.4 (1.1)	5.6 (1.2)	5.8 (1.2)	5.8 (1.2)
Blood pressure, mm Hg				
Conventional systolic	120.8 (16.6)	127.0 (14.5)	145.4 (23.6)	148.3 (22.4)
Conventional diastolic	74.0 (9.1)	82.5 (9.2)	79.7 (10.5)	88.6 (11.4)
24-h systolic	113.0 (6.9)	119.8 (4.0)	132.8 (8.0)	138.9 (11.3)
24-h diastolic	67.7 (4.4)	78.3 (2.9)	70.7 (3.5)	83.3 (6.4)
Daytime systolic	119.0 (8.5)	126.0 (6.3)	138.8 (9.7)	145.1 (12.3)
Daytime diastolic	72.8 (5.7)	83.8 (4.7)	74.9 (5.2)	88.2 (7.4)
Nighttime systolic	102.6 (8.3)	108.4 (7.3)	121.4 (12.5)	127.1 (14.6)
Nighttime diastolic	58.9 (5.6)	68.1 (6.0)	62.7 (5.6)	74.0 (8.7)

The 24-h systolic/diastolic BP threshold for hypertension was 125/75 mmHg by 2017 AHA/ACC criteria. Normotension refers to those with both systolic/diastolic BPs lower than the cutoff values, whereas combined hypertension refers to those with both systolic/diastolic BPs equal to or higher than the cutoff values. Isolated systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. Diabetes was a fasting plasma glucose level of  $\geq 7.0$  mmol/L or use of antidiabetic agents. ACC indicates American College of Cardiology; AHA, American Heart Association; BP, blood pressure; and CVD, cardiovascular disease.



**Figure. Sex- and age-standardized cumulative incidence of total mortality and cardiovascular (CV) event by hypertensive categories.**

Relative to normotension, isolated diastolic hypertension was not associated with increased risk of death or CV events when defined according to 2017 American Heart Association/American College of Cardiology criteria. The 24-h systolic/diastolic ambulatory blood pressure (BP) thresholds were 125/75 mm Hg by 2017 American Heart Association/American College of Cardiology (A and B) and 130/80 mm Hg by 2018 European Society of Cardiology (C and D) definitions. Normotension refers to those with both systolic/diastolic BPs lower than the cutoff values, whereas combined hypertension refers to those with both systolic/diastolic BPs equal to or higher than the cutoff levels. Isolated systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. Tabulated data are the number of participants at risk by hypertensive categories at 5-y intervals. *P* values show significance for comparison with the normotensive group.

In Cox regression analyses adjusted for cohort, sex, age, body mass index, smoking status, alcohol drinking status, serum cholesterol levels, antihypertensive drug treatment use, diabetes, and history of cardiovascular disease (Table 2), there was no independent association in the sample overall between IDH by the 2017 ACC/AHA criteria and either death (hazard ratio, 0.95 [95% CI, 0.79–1.13]) or cardiovascular events (hazard ratio, 1.14 [95% CI,

0.94–1.40]), compared with normotension. By contrast, IDH by the 2018 ESC criteria was independently associated with risk for cardiovascular events (hazard ratio, 1.44 [95% CI, 1.12–1.85]; Table 2), but not death. Consistent with the above-described excesses in crude events and cumulative incidence rates, ISH and combined hypertension by both sets of diagnostic criteria also demonstrated excess adjusted risk in the Cox models, relative to normotension.

**Table 2. Multivariable-Adjusted HR in Relation to Hypertension Categories by 24-Hour BP**

Characteristic	Total mortality (n=2836)		CV event (n=2049)	
	HR (95% CI)	P value	HR (95% CI)	P value
2017 AHA/ACC criteria				
Normotensive (n=5418)	Reference		Reference	
Isolated diastolic (n=1129)	0.95 (0.79–1.13)	0.55	1.14 (0.94–1.40)	0.19
Isolated systolic (n=1325)	1.16 (1.04–1.29)	0.008	1.35 (1.18–1.53)	<0.001
Combined (n=3263)	1.35 (1.23–1.48)	<0.001	1.73 (1.55–1.93)	<0.001
2018 ESC criteria				
Normotensive (n=7391)	Reference		Reference	
Isolated diastolic (n=574)	1.22 (0.96–1.56)	0.11	1.44 (1.12–1.85)	0.004
Isolated systolic (n=1429)	1.36 (1.24–1.50)	<0.001	1.53 (1.37–1.71)	<0.001
Combined (n=1741)	1.39 (1.26–1.53)	<0.001	1.86 (1.66–2.08)	<0.001

The 24-h systolic/diastolic BP thresholds were 125/75 mm Hg by 2017 AHA/ACC and 130/80 mm Hg by 2018 ESC definitions. Normotension refers to those with both systolic/diastolic BPs lower than the cutoff values, while combined hypertension refers to those with both systolic/diastolic BPs equal to or higher than the cutoff values. Isolated systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. HRs express the relative risk compared with the normotensive group as reference and were adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, antihypertensive drug intake, history of cardiovascular disease, and diabetes. ACC indicates American College of Cardiology; AHA, American Heart Association; BP, blood pressure; CV, cardiovascular; CVD, CV disease; ESC, European Society of Cardiology; and HR, hazard ratio.

The above results were almost identical in analyses of the subgroup of 8873 IDACO participants who were not on BP medication at baseline (Table S3). Similarly, when modeling participants on the basis of ABPM values at night, the results were again almost identical as for 24-hour readings, except that nocturnal IDH by the 2018 ESC criteria was no longer associated with cardiovascular events (results for full cohort in Table 3 and for the subgroup not on BP medication at baseline in Table S4).

### Further Sensitivity Analyses

In sensitivity analyses, we further adjusted the categorical BP exposures (ie, IDH, ISH, and combined hypertension)

for either diastolic BP or systolic BP values as baseline continuous covariables (Table S5 and Table S6). With further adjustment for diastolic BP as a continuous baseline covariable, the results from the categorical analyses were consistent with the main results presented in Tables 2 and 3. By contrast, with further adjustment for systolic BP as a continuous baseline covariable, there was no longer an association between IDH by the 2018 ESC definition and cardiovascular events. Second, for each of the individual outcomes that comprised the composite cardiovascular event end point, we repeated all of the analyses described above and found that IDH according to 24-hour ABPM criteria (by either guideline) was also not associated with any of these individual outcomes

**Table 3. Multivariable-Adjusted HR in Relation to Hypertension Categories by Nighttime BP**

Characteristic	Total mortality (n=2836)		CV event (n=2049)	
	HR (95% CI)	P value	HR (95% CI)	P value
2017 AHA/ACC criteria				
Normotensive (n=4766)	Reference		Reference	
Isolated diastolic (n=772)	0.99 (0.81–1.21)	0.94	1.15 (0.92–1.45)	0.22
Isolated systolic (n=1542)	1.14 (1.02–1.27)	0.025	1.35 (1.18–1.55)	<0.001
Combined (n=4055)	1.28 (1.17–1.40)	<0.001	1.62 (1.45–1.80)	<0.001
2018 ESC criteria				
Normotensive (n=7362)	Reference		Reference	
Isolated diastolic (n=834)	1.08 (0.91–1.28)	0.38	1.12 (0.92–1.36)	0.26
Isolated systolic (n=979)	1.29 (1.15–1.43)	<0.001	1.44 (1.36–1.64)	<0.001
Combined (n=1960)	1.43 (1.31–1.57)	<0.001	1.76 (1.58–1.96)	<0.001

The nighttime systolic/diastolic BP thresholds were 110/65 mm Hg by 2017 AHA/ACC and 120/70 mm Hg by 2018 ESC definitions. Normotension refers to those with both systolic/diastolic BPs lower than the cutoff values, while combined hypertension refers to those with both systolic/diastolic BPs equal to or higher than the cutoff levels. Isolated systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. HRs express the relative risk compared with the normotensive group as reference and were adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, antihypertensive drug intake, history of cardiovascular disease, and diabetes. ACC indicates American College of Cardiology; AHA, American Heart Association; BP, blood pressure; CV, cardiovascular; ESC, European Society of Cardiology; and HR, hazard ratio.

in isolation (Tables S7 and S8). Finally, third, analyses among the 9844 participants without a baseline history of cardiovascular disease produced consistent results (Tables S9 and S10).

### Analyses Stratified by Age and Sex

After stratification of the whole IDACO cohort into participants younger than 50 and participants of 50 years or older, there was evidence for higher crude rates of cardiovascular events among younger persons with IDH using 2017 ACC/AHA criteria (3.71 per 1000 person-years) compared with younger persons with normal BP (1.08 per 1000 person-years). By contrast, crude cardiovascular event rates among those aged 50 or more appeared lower in the IDH subgroup versus normotension (Table S11).

In adjusted Cox models, there was a statistically significant 3-fold increase in adjusted relative risk for cardiovascular events among IDACO participants younger than 50 who had IDH on 24-hour ABPM by 2017 ACC/AHA criteria, relative to young participants with normotension (Table 4). Furthermore, there was strong evidence of effect modification on the basis of age ( $P$  interaction <0.001) and IDACO participants 50 years or older with IDH had no excess cardiovascular risk compared to normotension. There was also a suggestion of effect modification by age on the association between IDH using the 2018 ESC criteria and cardiovascular events; with marginal evidence for higher risk in younger adults than older adults ( $P$  interaction =0.06). In contrast to cardiovascular events, IDH on 24-hour ABPM (either by 2017 ACC/AHA or by 2018 ESC criteria) was not significantly associated with mortality at any age

and there was no evidence of interaction on the basis of age (Table 4). Similarly, for both the 2018 ESC or 2017 ACC/AHA criteria, the risks of total mortality and cardiovascular events associated with IDH were similar among men and women in the whole IDACO cohort ( $P$  interaction =0.10, Tables S12 and S13).

### DISCUSSION

In this international study of adults with 24-hour ABPM recordings, 2 interesting and novel findings become evident. First, we found no association of IDH, as defined by the 2017 ACC/AHA guideline and using 24-hour ABPM readings, with adverse outcomes in the sample overall. By contrast and concordant with prior IDACO reports,<sup>18</sup> IDH on 24-hour ABPM as defined by the 2018 ESC guideline was associated with cardiovascular events, although not with death. The second observation, which addresses an issue of controversy<sup>12</sup>, was that after stratifying the study sample by age, IDH on 24-hour ABPM was associated with increased risk for cardiovascular events (both for the 2017 ACC/AHA and the 2018 ESC definitions of IDH) among participants younger than 50 years only.

### ACC/AHA Versus ESC Definitions of IDH Among Adults of All Ages

The first main finding from this IDACO report is consistent with prior research.<sup>5,11</sup> By using 24-hour and nocturnal ABPM recordings, the current results are an important validation of the report by McEvoy et al,<sup>5</sup> which analyzed adults of all ages participating in a number of US cohorts who had BP values collected at a single point in time as part of a research study visit. The IDACO

**Table 4. Multivariable-Adjusted HR in Relation to Hypertension Categories After Stratification by Age**

Characteristic	Total mortality				$P_{int}$	CV events				$P_{int}$
	Age<50		Age≥50			Age<50		Age≥50		
	HR (95% CI)	$P$ value	HR (95% CI)	$P$ value	HR (95% CI)	$P$ value	HR (95% CI)	$P$ value		
2017 AHA/ACC criteria										
Normotensive	Reference		Reference			Reference		Reference		
Isolated diastolic	1.66 (0.96–2.86)	0.068	0.91 (0.75–1.10)	0.31	0.076	2.87 (1.72–4.80)	<0.001	0.98 (0.78–1.23)	0.87	<0.001
Isolated systolic	0.68 (0.21–2.20)	0.52	1.14 (1.03–1.28)	0.015	0.28	0.74 (0.22–2.43)	0.62	1.33 (1.17–1.52)	<0.001	0.45
Combined	2.08 (1.33–3.25)	0.0013	1.33 (1.21–1.46)	<0.001	0.15	2.39 (1.47–3.89)	<0.001	1.68 (1.50–1.88)	<0.001	0.092
ESC 2018 criteria										
Normotensive	Reference		Reference			Reference		Reference		
Isolated diastolic	1.82 (0.93–3.57)	0.080	0.91 (0.75–1.10)	0.22	0.31	2.41 (1.30–4.45)	0.0052	1.31 (0.99–1.72)	0.058	0.058
Isolated systolic	0.98 (0.39–2.46)	0.97	1.36 (1.24–1.49)	<0.001	0.39	1.48 (0.66–3.31)	0.34	1.52 (1.35–1.70)	<0.001	0.76
Combined	2.28 (1.38–3.78)	0.0013	1.37 (1.24–1.51)	<0.001	0.097	2.34 (1.38–4.00)	0.0017	1.82 (1.63–2.04)	<0.001	0.24

The 24-h systolic/diastolic BP thresholds were 125/75 mmHg by 2017 AHA/ACC and 130/80 mmHg by 2018 ESC definitions. Normotension refers to those with both systolic/diastolic BPs lower than the cutoff values, while combined hypertension refers to those with both systolic/diastolic BPs equal to or higher than the cutoff levels. Isolated systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. HRs express the relative risk compared with the normotensive group in the age stratification as reference and were adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, antihypertensive drug intake, history of cardiovascular disease and diabetes.  $P_{int}$  is for the interaction between hypertension classifications and age group. ACC indicates American College of Cardiology; AHA, American Heart Association; BP, blood pressure; CV, cardiovascular; ESC, European Society of Cardiology; HR, hazard ratio; and  $P_{int}$ ,  $P$  interaction.

results presented here also align with findings from the UK Biobank.<sup>11</sup> In all of these reports, there was no excess cardiovascular risk associated with IDH by the 2017 ACC/AHA definition when all participants, irrespective of age, were included in analyses. An advantage of our IDACO data is that the use of 24-hour ABPM values allows for a more precise measurement of the IDH exposure than has previously been possible, even allowing for the rigorous methods used to record BP in the prior analyses.<sup>5,11</sup>

Therefore, these IDACO data challenge prior reports from four large clinical registries, which have suggested a modest increase in adjusted risk for IDH by the 2017 ACC/AHA definition among adults of all ages.<sup>4,10,19,20</sup> These registries studied adults attending routine clinical care visits (thereby introducing the possibility of some confounding by indication) and who had routine, non-standardized, clinical measurement, and documentation of BP. It is known that routine clinical measurement of BP and recording in electronic health records are not as accurate as standardized assessments undertaken as part of rigorous epidemiological studies like IDACO (this is true in particular for diastolic BP).<sup>21</sup>

This IDACO analysis also confirms data from UK Biobank,<sup>11</sup> and elsewhere,<sup>8</sup> demonstrating an increased risk for events among adults of all ages with IDH as defined by the 2018 ESC criteria. The apparent conflict between the 2017 ACC/AHA and 2018 ESC definitions of IDH can be explained by the former definition requiring a diastolic BP  $\geq 80$  mmHg, whereas the latter requires a diastolic BP  $\geq 90$  mmHg. This suggests that, among all adults with controlled systolic BP, risk for cardiovascular events is low when diastolic BP is between 80 and 89 mmHg but increases once diastolic BP is  $\geq 90$  mmHg.

### ACC/AHA Definition of IDH and Outcomes in Young Versus Old Adults

The second main finding from this IDACO analysis suggests that, by contrast to adults of all ages, the 2017 ACC/AHA definition of IDH may be a specific prognostically adverse feature in young adults aged  $< 50$  years. This question is important for several reasons. First, IDH is more common in younger adults,<sup>22</sup> and about half of those newly eligible for a diagnosis of IDH since 2017 ACC/AHA guidelines are aged  $< 50$  years.<sup>5</sup> Second, the only prior report suggesting interaction by age in the association between the 2017 ACC/AHA definition of IDH and events comprised of routinely collected BP data from a large clinical registry and may have consequently had methodological biases for the reasons outlined above.<sup>9,10</sup> Prior reports of cohorts with rigorous BP measurements that looked for age interaction in the association between the 2017 ACC/AHA IDH definition and events have suggested that young adults were not at increased risk, although these same cohorts

included few younger adults and so may have been underpowered.<sup>11</sup> Therefore, it has been unclear whether young adults have increased risk for events when IDH by the 2017 ACC/AHA definition is ascertained using research-quality BP measurements.

In IDACO, we found that younger adults with IDH by the 2017 ACC/AHA definition and measured using 24-hour ABPM did indeed have increased risk for cardiovascular events (but not death). This finding utilizing rigorous ascertainment of BP with ABPM confirms suggestions from prior studies (which used less valid routine clinical assessment of BP)<sup>9,10</sup> that there is an age-related interaction in the association between the 2017 ACC/AHA definition of IDH and events, with far stronger excesses in relative risk among young adults aged less than 50 years compared with older adults. The physiological reasons for this age interaction are not fully known; however, a few considerations are worth noting; (1) diastolic BP has been shown to have more prognostic significance in the young versus the old<sup>18</sup> and (2) the prevalence of elevated diastolic BP is as low as 10% (or less) among adults over 70 years,<sup>4</sup> and, therefore, some cases of IDH in older IDACO adults may have been misclassified due to BP measurement error on both office and 24-hour ABPM (noting that increased vascular stiffness with aging increases the likelihood of the fifth Korotkoff sound being absent, which could result in falsely elevated diastolic BP readings and, therefore, false positive IDH ascertainment).

Finally, several factors might help to explain why this IDACO age-stratified finding contrasts with the prior epidemiological studies using research-grade BP measurements,<sup>5,11</sup> none of which have found an age interaction for the 2017 ACC/AHA definition of IDH. First, the very large IDACO dataset is well powered to test this interaction effect, whereas prior studies may not have been; second, the IDACO sample is younger on average than some of the prior analyses<sup>5</sup> testing the 2017 ACC/AHA definition of IDH; and, third, by using 24-hour ABPM readings, our IDACO data were less likely to include spurious or artifactual readings of elevated diastolic BP that may be more commonly seen in BP assessments at a single point in time.

### Limitations

This observational analysis has limitations. First, we cannot exclude residual confounding, including but not limited to lipid-lowering and antiplatelet therapies. Second, 24-hour BP and antihypertensive drug treatment status were only recorded at baseline and could therefore not be adjusted for as a time-dependent covariables. Furthermore, our sensitivity analysis excluding persons on antihypertensives at baseline may have included some persons subsequently started on therapy. Third, our pre-specified adjustment model did not control for baseline



heart rate; however, in further sensitivity analyses adding heart rate to this model, the results remained quantitatively and qualitatively very similar (data not shown). Fourth, there might be misclassification bias in the assessment of the cardiovascular study end points.<sup>23</sup> However, all-cause mortality does not require any adjudication and is therefore not subject to this bias. Fifth, diastolic BP levels as assessed using automated oscillometric ABPM devices can sometimes overestimate true diastolic BP as measured using intra-arterial transducers. In addition, although categorical analyses of diastolic BP have implications for clinical care (given the use of specific BP thresholds to define hypertension), it is also worth noting that BP is a continuous pathophysiologic exposure variable. Sixth, our findings of interaction by age could represent the play of chance; however, they were prespecified and the highly significant *P* interaction values also make this less likely, as do prior data from registry studies suggesting significant interaction by age on the association between IDH (by both 2017 ACC/AHA and by 2018 ESC criteria) and cardiovascular events.<sup>10</sup> Finally, eighth, no Black participants were included in the IDACO database, and caution should be taken when extrapolating our results to races and ethnicities that were not included.

## Perspectives

This prospective cohort analysis of 24-hour ambulatory BP data did not demonstrate an association between the 2017 ACC/AHA definition of IDH and outcomes in the IDACO sample overall. However, significant effect modification was noted on the basis of age and persons younger than 50 years with IDH as defined by the 2017 ACC/AHA criteria for 24-hour ABPM readings did have evidence for increased risk of cardiovascular events. These data, using rigorous 24-hour ABPM assessments, indicate that the clinical implications of IDH differ greatly based on the patient's age. Older persons (>50 years) with evidence of IDH appear to be a little risk as long as systolic BPs are controlled. However, younger persons with IDH do have elevated relative risk for cardiovascular events and may therefore benefit from intensive lifestyle interventions and, where clinically appropriate, antihypertensive medications.

## ARTICLE INFORMATION

Received May 26, 2021; accepted August 12, 2021.

This article is dedicated to Professor Y. Nikitin, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russian Federation, cofounder of the European Project of Genes in Hypertension, and principal investigator of the studies in Novosibirsk, who passed away on April 2, 2021.

### Affiliations

National University of Ireland Galway, School of Medicine, and National Institute for Prevention and Cardiovascular Health, Ireland (J.W.M.). Department of Cardiol-

ogy, Shanghai General Hospital (W.-Y.Y.) and Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation, Shanghai Institute of Hypertension, Ruijin Hospital (Y.L., J.-G.W.), Shanghai Jiao Tong University School of Medicine, China. Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences (Z.-Y.Z., L.T., J.D.M., K.A.), Centre for Molecular and Vascular Biology, KU Leuven Department of Cardiovascular Sciences (T.V.), and Biomedical Sciences Group, Faculty of Medicine (J.A.S.), University of Leuven, Belgium. Centro de Nefrología and Departamento de Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay (J.B.). The Steno Diabetes Center Copenhagen, Gentofte, and Center for Health, Capital Region of Denmark, Copenhagen (T.W.H.). Tohoku Institute for Management of Blood Pressure, Sendai, Japan (K.A., T.O., Y.I.). Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A., T.O.). Stroke and Hypertension Unit, Connolly Hospital, Geriatric Medicine, Dublin, Ireland (E.D.). The First Department of Cardiology, Interventional Electrophysiology and Hypertension, Jagiellonian University Medical College, Krakow, Poland (K.S.-S., K.K.-J.). Institute of Internal and Preventive Medicine and Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russian Federation (S.M.). Department of Medicine, University of Padua, Italy (E.C.). Section of Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Sweden (L.L.). Faculty of Medicine, Charles University, Pilsen, Czech Republic (J.F.). Laboratorio de Neurociencias and Instituto Cardiovascular, Universidad del Zulia, Maracaibo, Venezuela (G.E.M.). Department of Biomedical Sciences, Division of Neuroscience and Department of Human Genetics, University of Texas Rio Grande Valley School of Medicine, Brownsville (G.E.M.). Asociación Española Primera de Socorros Mutuos, Montevideo, Uruguay (E.S.). Hypertension Unit, Department of Hypertension and Diabetology, Medical University of Gdansk, Poland (K.N.). Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Ireland (E.O.). Research Institute Alliance for the Promotion of Preventive Medicine, Mecehelen, Belgium (J.A.S.).

### Acknowledgments

We gratefully acknowledge the study participants and the contribution of clerical staff at the Studies Coordinating Center (Vera De Leebeek and Renilde Wolfs).

### Sources of Funding

Belgium: European Union (HEALTH-F7-305507 HOMAGE), European Research Council (Advanced Researcher Grant 2011-294713-EPLORE and Proof-of-Concept Grant 713601-uPROPHET), European Research Area Net for Cardiovascular Diseases (JTC2017-046-PROACT) and Research Foundation Flanders, Ministry of the Flemish Community, Brussels, Belgium (G.0881.13); China: National Natural Science Foundation of China (grants 81170245, 81270373, 81470533, and 91639203), Ministry of Science and Technology (2013CB530700 and the China-European Union Collaboration Grant 1012), Beijing, China, and the Shanghai Commissions of Science and Technology (grants 14ZR1436200 and 15XD1503200 and Shanghai Pujiang Program-20PJ1412700) and Education (Gaofeng Clinical Medicine Grant Support 20152503); The Czech Republic: European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550) and Charles University Research Fund (project P36); Denmark: Danish Heart Foundation (grant 01-2-9-9A-22914) and Lundbeck Fonden (grant R32-A2740); Ireland: the Irish Allied Bank; Italy: European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550); Japan: Ministry of Culture, Sports, Science and Technology (17H04126, 17K15853, 17K19930, 18K09674, 18K09904, 18K17396, 19K19466, 19H03908, 19K10662, and 20K08612), ACRO Incubation Grants of Teikyo University, Japan Atherosclerosis Prevention Fund, Ministry of Health, Labor and Welfare (H29-Junkankitō-Ippan-003 and 20FA1002), Academic Contributions from Pfizer Japan, Inc, and scholarship donations from Chugai Pharmaceutical, Co, Ltd, Daiichi Sankyo Company, Research Support from Astellas Pharma, Inc, and Takeda Pharmaceutical, Co, Ltd; The Health Care Science Institute Research Grant; Health Science Center Research Grant; Takeda Science Foundation; Poland (Gdańsk): European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550); Poland (Kraków): European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550) and Foundation for Polish Science; The Russian Federation: European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550) and Russian Academy of Science (AAAA-A17-117112850280-2); Uruguay: Asociación Española Primera en Salud; Venezuela: The National Institute of Aging and the Fogarty International Center (grant 1-R01AG036469 A1), the National Institutes of Health and National Institute of Aging (grant 1 R03 AG054186-01), FONACIT, Caracas (grant G-97000726), and FundaConCiencia, Maracaibo (grant LOCTI/008-2008). The Research Institute Alliance for the Promotion of Preventive Medicine (URL:

www.appremed.org) received a nonbinding grant from OMRON Healthcare, Co, Ltd, Kyoto, Japan.

## Disclosures

K. Asayama reports grants from Omron Healthcare, personal fees from Takeda Pharmaceuticals, outside the submitted work; K. Narkiewicz reports personal fees from Berlin-Chemie/Menarini, personal fees from Egis, personal fees from Idorsia, personal fees from Gedeon Richter, personal fees from Krka, personal fees from Bausch, personal fees from Polpharma, personal fees from Recordati, personal fees from Servier, outside the submitted work; J.A. Staessen reports that the nonprofit research institute "Alliance for the Promotion of Preventive Medicine" (registration number at the Belgian Registry of Enterprises: 739849385; URL: <https://www.appremed.org>) received a nonbinding grant from OMRON Healthcare, Co, Ltd, Kyoto, Japan; J.-G. Wang reports grants and personal fees from Omron, personal fees from Novartis, personal fees from Servier, outside the submitted work. The other authors report no conflicts.

## REFERENCES

1. Staessen JA, Byttebier G, Buntinx F, Celis H, O'Brien ET, Fagard R; for the Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. *JAMA*. 1997;278:1065–1072. doi: 10.1001/jama.1997.03550130039034
2. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. *JAMA*. 1999;282:539–546. doi: 10.1001/jama.282.6.539
3. Yang WY, Melgarejo JD, Thijs L, Zhang ZY, Boggia J, Wei FF, Hansen TW, Asayama K, Ohkubo T, Jeppesen J, et al; International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. *JAMA*. 2019;322:409–420. doi: 10.1001/jama.2019.9811
4. Flint AC, Conell C, Ren X, Banki NM, Chan SL, Rao VA, Melles RB, Bhatt DL. Effect of systolic and diastolic blood pressure on cardiovascular outcomes. *N Engl J Med*. 2019;381:243–251. doi: 10.1056/NEJMoa1803180
5. McEvoy JW, Daya N, Rahman F, Hoogeveen RC, Blumenthal RS, Shah AM, Ballantyne CM, Coresh J, Selvin E. Association of isolated diastolic hypertension as defined by the 2017 ACC/AHA blood pressure guideline with incident cardiovascular outcomes. *JAMA*. 2020;323:329–338. doi: 10.1001/jama.2019.21402
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. *JAMA*. 2003;289:2560–2572. doi: 10.1001/jama.289.19.2560
7. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2018;71:e127–e248.
8. Quinn S, McEvoy JW. Systolic and diastolic blood pressure and cardiovascular outcomes. *N Engl J Med*. 2019;381:1690–1691. doi: 10.1056/NEJMc1911059
9. Lee H, Yano Y, Cho SMJ, Park JH, Park S, Lloyd-Jones DM, Kim HC. Cardiovascular risk of isolated systolic or diastolic hypertension in young adults. *Circulation*. 2020;141:1778–1786. doi: 10.1161/CIRCULATIONAHA.119.044838
10. Lee H, Yano Y, Cho SMJ, Park S, Lloyd-Jones DM, Kim HC. Cardiovascular risk of isolated diastolic hypertension defined by the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline: a Nationwide Age-Stratified Cohort Study. *Hypertension*. 2020;76:e44–e46. doi: 10.1161/HYPERTENSIONAHA.120.16018
11. McGrath BP, Kundu P, Daya N, Coresh J, Selvin E, McEvoy JW, Chatterjee N. Isolated diastolic hypertension in the UK Biobank: comparison of ACC/AHA and ESC/NICE Guideline Definitions. *Hypertension*. 2020;76:699–706. doi: 10.1161/HYPERTENSIONAHA.120.15286
12. Jacobsen AP, Al Rifai M, Arps K, Whelton SP, Budoff MJ, Nasir K, Blaha MJ, Psaty BM, Blumenthal RS, Post WS, et al. A cohort study and meta-analysis of isolated diastolic hypertension: searching for a threshold to guide treatment. *Eur Heart J*. 2021;42:2119–2129. doi: 10.1093/eurheartj/ehab111
13. Hansen TW, Kikuya M, Thijs L, Li Y, Boggia J, Björklund-Bodegård K, Torp-Pedersen C, Jeppesen J, Ibsen H, Staessen JA. Diagnostic thresholds for ambulatory blood pressure moving lower: a review based on a meta-analysis - Clinical implications. *J Clin Hypertens*. 2008;10:377–381. doi: 10.1111/j.1751-7176.2008.07681.x
14. Li Y, Thijs L, Hansen TW, Kikuya M, Boggia J, Richart T, Metoki H, Ohkubo T, Torp-Pedersen C, Kuznetsova T, et al; International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes Investigators. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. *Hypertension*. 2010;55:1040–1048. doi: 10.1161/HYPERTENSIONAHA.109.137273
15. Yang WY, Thijs L, Zhang ZY, Asayama K, Boggia J, Hansen TW, Ohkubo T, Jeppesen J, Stolarz-Skrzypek K, Maljutina S, et al; International Database; on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) Investigators. Evidence-based proposal for the number of ambulatory readings required for assessing blood pressure level in research settings: an analysis of the IDACO database. *Blood Press*. 2018;27:341–350. doi: 10.1080/08037051.2018.1476057
16. Fagard R, Brguljan J, Thijs L, Staessen J. Prediction of the actual awake and asleep blood pressures by various methods of 24 h pressure analysis. *J Hypertens*. 1996;14:557–563. doi: 10.1097/00004872-199605000-00003
17. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, et al; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39:3021–3104. doi: 10.1093/eurheartj/ehy339
18. Li Y, Wei FF, Thijs L, Boggia J, Asayama K, Hansen TW, Kikuya M, Björklund-Bodegård K, Ohkubo T, Jeppesen J, et al; International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) Investigators. Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations. *Circulation*. 2014;130:466–474. doi: 10.1161/CIRCULATIONAHA.113.004876
19. Kaneko H, Itoh H, Yotsumoto H, Kiriya H, Kamon T, Fujiu K, Morita K, Michihata N, Jo T, Takeda N, et al. Association of isolated diastolic hypertension based on the cutoff value in the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines with subsequent cardiovascular events in the general population. *J Am Heart Assoc*. 2020;9:e017963. doi: 10.1161/JAHA.120.017963
20. Wu S, Ji C, Shi J, Chen S, Huang Z, Jonas JB. Isolated diastolic hypertension as defined by the 2017 American College of Cardiology/American Heart Association blood pressure guideline and incident cardiovascular events in Chinese. *J Hypertens*. 2021;39:519–525. doi: 10.1097/HJH.0000000000002659
21. Blank SG, Mann SJ, James GD, West JE, Pickering TG. Isolated elevation of diastolic blood pressure. Real or artifactual? *Hypertension*. 1995;26:383–389. doi: 10.1161/01.hyp.26.3.383
22. Franklin SS, Pio JR, Wong ND, Larson MG, Leip EP, Vasan RS, Levy D. Predictors of new-onset diastolic and systolic hypertension: the Framingham Heart Study. *Circulation*. 2005;111:1121–1127. doi: 10.1161/01.CIR.0000157159.39889.EC
23. Mieno MN, Tanaka N, Arai T, Kawahara T, Kuchiba A, Ishikawa S, Sawabe M. Accuracy of death certificates and assessment of factors for misclassification of underlying cause of death. *J Epidemiol*. 2016;26:191–198. doi: 10.2188/jea.EJ20150010

# Hypertension

## Supplementary Data

### Isolated Diastolic Hypertension in the IDACO Study: An Age-Stratified Analysis Using 24-hour Ambulatory Blood Pressure Measurements\*

John W. McEvoy, MBBCh\*; Wen-Yi Yang, MD\*; Lutgarde Thijs, MSc; Zhen-Yu Zhang, MD; Jesus D. Melgarejo, MD; José Boggia, MD; Tine W. Hansen, MD; Kei Asayama, MD; Takayoshi Ohkubo, MD; Eamon Dolan, MD; Katarzyna Stolarz-Skrzypek, MD; Sofia Malyutina, MD; Edoardo Casiglia, MD; Lars Lind, MD; Jan Filipovský, MD; Gladys E. Maestre, MD; Yan Li, MD; Ji-Guang Wang, MD; Yutaka Imai, MD; Kalina Kawecka-Jaszcz, MD; Edgardo Sandoya, MD; Krzysztof Narkiewicz, MD; Eoin O'Brien, MD; Thomas Vanassche, MD, Jan A. Staessen, MD; on behalf of the International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) Investigators.

\*J.W. McEvoy and W.Y. Yang are joint first authors.

#### Correspondence:

Jan A. Staessen, MD, PhD,  
Research Institute Alliance for the Promotion of Preventive Medicine Leopoldstraat 59,  
BE-2800 Mechelen, Belgium

Telephone: +32-15-41-1747; +32-47-632-4928 (mobile)

Facsimile: +32-15-41-4542

email: [jan.staessen@apremed.org](mailto:jan.staessen@apremed.org); [jan.staessen@med.kuleuven.be](mailto:jan.staessen@med.kuleuven.be)

This Online Supplement formed part of the original submission and has been peer reviewed.

## Table of Contents

<b>Expanded Methods</b>	Page e3
<b>References</b>	Page e4
<b>Table S1</b> Recruitment and Follow-Up by Cohort	Page e5
<b>Table S2</b> Ambulatory Blood Pressure Monitoring by Cohort	Page e6
<b>Table S3</b> Hazard Ratio by 24-H BP Criteria among 8873 Untreated Participants	Page e7
<b>Table S4</b> Hazard Ratio by Nighttime BP Criteria among 8873 Untreated Participants	Page e8
<b>Table S5</b> Hazard Ratio by 24-H BP Criteria Adjusted for 24-H BP Levels	Page e9
<b>Table S6</b> Hazard Ratio by Nighttime BP Criteria Adjusted for Nighttime BP Levels	Page e10
<b>Table S7</b> Hazard Ratio for Secondary End Points by 24-H BP Criteria	Page e11
<b>Table S8</b> Hazard Ratio for Secondary End Points by Nighttime BP Criteria	Page e12
<b>Table S9</b> Hazard Ratio by 24-H BP Criteria among 9948 Participants without CVD at baseline	Page e13
<b>Table S10</b> Hazard Ratio by Nighttime BP Criteria among 9948 Participants without CVD at baseline	Page e14
<b>Table S11</b> Number of Participants and Events by 24-H Hypertension Categories and Age Strata	Page e15
<b>Table S12</b> Number of Participants and Events by 24-H Hypertension Categories and Gender	Page e16
<b>Table S13</b> Hazard Ratio by 24-H Hypertension Categories and Gender	Page e17

## Expanded Methods

### Study Participants

All studies received ethical approval and adhered to the principles of the Declaration of Helsinki. Participants gave written informed consent. Previous publications describe the IDACO database in detail.<sup>3,14,15,18</sup> Population studies qualified for inclusion, if information on the office and the ambulatory blood pressure and cardiovascular risk factors was available at baseline and if follow-up included both fatal and nonfatal outcomes. Of the 13,111 people included in the database, we excluded 1976 because they were teenagers without events ( $n = 493$ ), or had an ambulatory blood pressure recording with fewer than six daytime and three nighttime readings ( $n = 1483$ ). Thus, the number of individuals statistically analyzed was 11,135. **Table S1** provides detailed information on the population sampling methods, timelines and country of recruitment.

### Blood Pressure Measurement

**Table S2** provides detailed information on blood pressure measurement. Nurses or physicians measured the conventional blood pressure with a standard mercury sphygmomanometers, or with validated auscultatory (USM-700F, UEDA Electronic Works, Tokyo, Japan) or oscillometric devices (OMRON HEM-705CP, Omron Corporation, Kyoto, Japan; Dinamap 8100, Critikon Inc., Tampa, FL), using the appropriate cuff size, with participants in the sitting or supine position. Hypertension was a conventional blood pressure of  $\geq 140$  mm Hg systolic or  $\geq 90$  mm Hg diastolic or use of antihypertensive drugs.

For ambulatory blood pressure monitoring, portable monitors were programmed to obtain ambulatory readings at 30-minute intervals throughout the whole day, or at intervals of 15, 20 or 30 minutes during daytime and at intervals of 20, 30, 40, 45 or 60 minutes during nighttime. All devices had passed validation and only oscillometric measurements were used for analysis. The same SAS macro processed all ambulatory recordings, which remained unedited or were only sparsely edited in Ohasama participants. We defined daytime as the interval from 10 AM to 8 PM in Europeans and South Americans and from 8 AM to 6 PM in Asians. The corresponding nighttime intervals ranged from midnight to 6 AM and from 10 PM to 4 AM, respectively. These short fixed clock-time intervals eliminate the transition periods in the morning and evening when blood pressure changes rapidly, resulting in daytime and nighttime blood pressure levels that are within 1–2 mm Hg of the awake and asleep levels. We weighted the within-subject means of the ambulatory blood pressure by the time interval between successive readings. Furthermore, we also defined the awake and asleep periods of the day in 7133 participants (64.1%), who had kept a diary during ambulatory blood pressure monitoring. Automated office blood pressure was the mean of the ambulatory recordings during the first recording hour, when the monitors were applied in a medical environment.

The dipping ratio was the nighttime divided by the daytime blood pressure level. We focused on systolic blood pressure, because mean age was 53.4 years and in older adults systolic blood pressure is the predominant risk factor. Diastolic pressure was analyzed to replicate findings for systolic pressure. Dipping ratio was defined as nighttime divided by daytime BP. In categorical analyses, extreme dipping, normal dipping, non-dipping and reverse dipping were dipping ratios of  $\leq 0.80$ ,  $>0.80$  to  $\leq 0.90$ ,  $>0.90$  to  $\leq 1.00$ , and  $>1.00$ , respectively.

**Other Measurements**

We used the questionnaires originally administered in each cohort to obtain information on each participant's medical history and smoking and drinking habits. Body mass index was body weight in kilograms divided by height in meters squared. We measured serum total cholesterol and blood glucose by automated enzymatic methods. Diabetes mellitus was the use of antidiabetic drugs, a fasting blood glucose of  $\geq 126$  mg/dL ( $\geq 7.0$  mmol/L), a random blood glucose of  $\geq 200$  mg/dL ( $\geq 11.1$  mmol/L), a self-reported diagnosis, or diabetes documented in practice or hospital records.

**References**

See main text

**Table S1. Recruitment and Follow-Up by Cohort**

Catchment Area	Sampling Frame	Recruitment		PR (%)	N° of Participants		Follow-Up	
		Timeline (Years)	Invitation		In Database	Analyzed	Last (Year)	Median in Years (5–95% Interval)
Ohasama, Iwate, Japan	People aged ≥40 years	1988–1994	Address list	78	1535	1535	2015	21.8 (4.7–26.8)
JingNing, Zhejiang, China	Family-based random sample	2003–2003	All villagers invited	62	360	352	2006	2.5 (2.3–2.6)
Oktyabrsky, Novosibirsk, Russian Federation	Family-based random sample	1999–2001	Address list	68	298	283	2009	8.8 (8.0–9.5)
Niepolomice, Kraków, Poland	Family-based random sample	1999–2008	Address list	54	413	355	2014	13.5 (6.1–14.3)
Gdańsk, Poland	Family-based random sample	2008–2010	Address list	90	215	202	2014	5.6 (4.7–6.7)
Pilsen, Czech Republic	Family-based random sample	2000–2001	Address list	82	174	159	2015	14.1 (13.8–14.4)
Padova, Italy	Family-based random sample	1999–2007	Address list	73	314	305	2013	13.3 (12.5–14.5)
Noordkempen, Belgium	Family-based random sample	1985–2008	Address list	78	2904	1430	12016	22.8 (7.9–26.2)
Uppsala, Sweden	Men aged 69–74 years	1991–1995	Population census	73	1143	1114	2015	15.1 (3.5–22.2)
Copenhagen County, Denmark	Stratified random sample of women and men aged 30, 40, 50 and 60 years	1993–1997	Population registry	83	2311	2148	2010	16.3 (5.1–17.3)
Dublin, Ireland	Bank employees working at branches across Ireland	1989–1991	All invited	14	981	933	2007	17.6 (16.4–18.2)
Maracaibo, Venezuela	City residents aged ≥55 years	1998–2008	Population census	71	604	590	2012	8.2 (1.7–13.7)
Montevideo, Uruguay	Age-stratified random sample	1995–1998	Members of a health insurance organization	78	1859	1729	2007	9.0 (4.2–10.7)

Abbreviation: PR, participation rate. The European Project on Genes in Hypertension included participants recruited in Novosibirsk, Kraków, Gdańsk, Pilsen and Padova. Participants from Padova were recruited in Mirano in the province of Venice and in Torrebelvicino and Valli del Pasubio in the province of Vicenza.

**Table S2. Ambulatory Blood Pressure Monitoring Devices by Cohort**

Study Cohorts	N° of Subjects	Monitoring Device	Programmed Reading Intervals minutes		N° of Readings					
			Day	Night	Programmed	Median	P5	P25	P75	P95
Ohasama, Iwate, Japan	1535	ABP-630, Nippon Colin	30	30	48	45	35	42	48	50
JingNing, Zhejiang, China	352	90207, SpaceLabs	20	45	65	56	52	55	56	57
Oktyabrsky, Novosibirsk, Russia	283	90202, SpaceLabs	15	30	76	71	56	65	75	78
Niepolomice, Kraków, Poland	355	90202, SpaceLabs	15	30	76	74	54	61	77	79
Gdańsk, Poland	202	TM-2430, A&D	20	45	65	62	50	59	64	64
Pilsen, Czech Republic	159	90202, SpaceLabs	20	45	65	75	54	70	80	82
Padova, Italy	305	90202, SpaceLabs	15	30	76	76	66	74	77	78
Noordkempen, Belgium	1430	90202, SpaceLabs	20	40	55	53	37	41	56	58
Uppsala, Sweden	1114	Accutacker II	20–30	20–60	41–72	65	44	52	75	84
Copenhagen County, Denmark	2148	TM-2421, A&D	15	30	80	80	67	78	81	83
Dublin, Ireland	933	90202 and 90207, Spacelabs	30	30	48	46	37	44	48	49
Maracaibo, Venezuela	590	90207, SpaceLabs	15	30	80	67	51	61	71	77
Montevideo, Uruguay	1729	90207, SpaceLabs	20	40	60	37	26	33	39	42

The TM-2421 and TM-2430 monitors implemented both an auscultatory and an oscillometric technique. However, only oscillometric readings were used for analysis. All devices passed validation.



**Table S3. Multivariable-Adjusted Hazard Ratio in Relation to Hypertension Categories by 24-H BP among 8,873 Untreated Participants**

Characteristic	Total Mortality (n=1754)		CV Event (n=1227)	
	HR (95%CI)	P value	HR (95%CI)	P value
<b>AHA/ACC 2017 criteria</b>				
Normotensive (n=4747)	Reference		Reference	
Isolated Diastolic (n=977)	0.84 (0.79–1.27)	0.77	1.24 (0.98–1.58)	0.072
Isolated Systolic (n=918)	1.22 (1.06–1.40)	0.006	1.38 (1.17–1.64)	<0.001
Combined (n=2231)	1.49 (1.33–1.67)	<0.001	1.85 (1.61–2.13)	<0.001
<b>ESC 2018 criteria</b>				
Normotensive (n=6373)	Reference		Reference	
Isolated Diastolic (n=450)	1.16 (0.85–1.59)	0.34	1.58 (1.16–2.16)	0.004
Isolated Systolic (n=921)	1.39 (1.23–1.57)	<0.001	1.52 (1.31–1.76)	<0.001
Combined (n=1129)	1.54 (1.36–1.75)	<0.001	2.00 (1.73–2.31)	<0.001

Abbreviations: BP, blood pressure; CI, 95% confidence interval; CV, cardiovascular; HR, Hazard ratio. The 24-h systolic/diastolic BP thresholds were 125/75 mm Hg by AHA/ACC 2017 and 130/80 mm Hg by ESC 2018. Normotension refers to those with both systolic/diastolic BPs were lower than the cut-off values, while combined hypertension refers to those with both systolic/diastolic BPs were equal to or higher than the cut-off values. Isolated systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. HRs express the relative risk compared with the normotensive group as reference and were adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, history of cardiovascular disease and diabetes mellitus.

**Table S4. Multivariable-Adjusted Hazard Ratio in Relation to Hypertension Categories by Nighttime BP among 8,873 Untreated Participants**

Characteristic	Total Mortality (n=1754)		CV Event (n=1227)	
	HR (95%CI)	P value	HR (95%CI)	P value
<b>AHA/ACC 2017 criteria</b>				
Normotensive (n=4198)	Reference		Reference	
Isolated Diastolic (n=661)	1.06 (0.84–1.33)	0.62	1.11 (0.84–1.46)	0.48
Isolated Systolic (n=1156)	1.18 (1.02–1.36)	0.027	1.38 (1.16–1.64)	<0.001
Combined (n=2858)	1.36 (1.22–1.52)	<0.001	1.74 (1.52–1.99)	<0.001
<b>ESC 2018 criteria</b>				
Normotensive (n=6320)	Reference		Reference	
Isolated Diastolic (n=653)	1.11 (0.90–1.37)	0.33	1.09 (0.84–1.41)	0.52
Isolated Systolic (n=620)	1.40 (1.21–1.62)	<0.001	1.71 (1.45–2.03)	<0.001
Combined (n=1280)	1.54 (1.37–1.73)	<0.001	1.87 (1.63–2.15)	<0.001

Abbreviations: BP, blood pressure; CI, 95% confidence interval; CV, cardiovascular; HR, Hazard ratio. The nighttime systolic/diastolic BP thresholds were 110/65 mm Hg by AHA/ACC 2017 and 120/70 mm Hg by ESC 2018. Normotension refers to those with both systolic/diastolic BPs were lower than the cut-off values, while combined hypertension refers to those with both systolic/diastolic BPs were equal to or higher than the cut-off levels. Isolated systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. HRs express the relative risk compared with the normotensive group as reference and were adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, history of cardiovascular disease and diabetes mellitus.

**Table S5. Multivariable-Adjusted Hazard Ratio Adjusted for Systolic or Diastolic 24-H BP**

Characteristic	Total Mortality (n=2836)		CV Event (n=2049)	
	HR (95%CI)	P value	HR (95%CI)	P value
<b>AHA/ACC 2017 criteria</b>				
<i>Adjusted for systolic BP</i>				
Normotensive (n=5418)	Reference		Reference	
Isolated Diastolic (n=1129)	0.91 (0.76–1.09)	0.29	1.04 (0.85–1.28)	0.68
Isolated Systolic (n=1325)	1.02 (0.90–1.15)	0.82	1.02 (0.88–1.18)	0.81
Combined (n=3263)	1.11 (0.97–1.27)	0.14	1.14 (0.97–1.33)	0.11
<i>Adjusted for diastolic BP</i>				
Normotensive (n=5418)	Reference		Reference	
Isolated Diastolic (n=1129)	0.91 (0.75–1.09)	0.32	1.04 (0.85–1.28)	0.80
Isolated Systolic (n=1325)	1.14 (1.02–1.27)	0.020	1.28 (1.12–1.46)	<0.001
Combined (n=3263)	1.26 (1.09–1.46)	0.002	1.34 (1.14–1.59)	<0.001
<b>ESC 2018 criteria</b>				
<i>Adjusted for systolic BP</i>				
Normotensive (n=7391)	Reference		Reference	
Isolated Diastolic (n=574)	1.18 (0.92–1.50)	0.20	1.30 (1.01–1.67)	0.039
Isolated Systolic (n=1429)	1.23 (1.09–1.39)	<0.001	1.17 (1.01–1.35)	0.035
Combined (n=1741)	1.20 (1.03–1.39)	0.020	1.26 (1.06–1.50)	0.008
<i>Adjusted for diastolic BP</i>				
Normotensive (n=7391)	Reference		Reference	
Isolated Diastolic (n=574)	1.17 (0.90–1.52)	0.24	1.25 (0.96–1.64)	0.10
Isolated Systolic (n=1429)	1.34 (1.21–1.48)	<0.001	1.45 (1.29–1.64)	<0.001
Combined (n=1741)	1.31 (1.12–1.54)	<0.001	1.53 (1.28–1.84)	<0.001

Abbreviations: BP, blood pressure; CI, 95% confidence interval; CV, cardiovascular; HR, Hazard ratio, were adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, antihypertensive drug intake, history of cardiovascular disease and diabetes mellitus, and 24-h systolic or diastolic BP.

**Table S6. Multivariable-Adjusted Hazard Ratio Adjusted for Systolic & Diastolic Nighttime BP**

Characteristic	Total Mortality (n=2836)		CV Event (n=2049)	
	HR (95%CI)	P value	HR (95%CI)	P value
<b>AHA/ACC 2017 criteria</b>				
<i>Adjusted for systolic BP</i>				
Normotensive (n=4766)	Reference		Reference	
Isolated Diastolic (n=772)	0.94 (0.77–1.15)	0.55	1.08 (0.88–1.36)	0.52
Isolated Systolic (n=1542)	0.95 (0.84–1.07)	0.37	1.05 (0.91–1.22)	0.49
Combined (n=4055)	0.94 (0.83–1.06)	0.31	1.08 (0.94–1.25)	0.28
<i>Adjusted for diastolic BP</i>				
Normotensive (n=4766)	Reference		Reference	
Isolated Diastolic (n=772)	0.86 (0.70–1.06)	0.16	0.96 (0.76–1.22)	0.73
Isolated Systolic (n=1542)	1.09 (0.97–1.22)	0.14	1.28 (1.12–1.47)	<0.001
Combined (n=4055)	1.01 (0.88–1.15)	0.90	1.18 (1.01–1.38)	0.039
<b>ESC 2018 criteria</b>				
<i>Adjusted for systolic BP</i>				
Normotensive (n=7362)	Reference		Reference	
Isolated Diastolic (n=834)	1.00 (0.85–1.20)	0.93	1.00 (0.83–1.22)	0.97
Isolated Systolic (n=979)	1.07 (0.94–1.23)	0.30	1.08 (0.92–1.26)	0.37
Combined (n=1960)	1.12 (0.98–1.29)	0.11	1.19 (1.01–1.39)	0.035
<i>Adjusted for diastolic BP</i>				
Normotensive (n=7362)	Reference		Reference	
Isolated Diastolic (n=834)	0.99 (0.82–1.20)	0.94	0.95 (0.77–1.18)	0.63
Isolated Systolic (n=979)	1.24 (1.11–1.39)	<0.001	1.35 (1.18–1.54)	<0.001
Combined (n=1960)	1.27 (1.09–1.48)	0.002	1.38 (1.15–1.64)	<0.001

Abbreviations: BP, blood pressure; CI, 95% confidence interval; CV, cardiovascular; HR, Hazard ratio, were adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, antihypertensive drug intake, history of cardiovascular disease and diabetes mellitus, and 24-h systolic or diastolic BP.

**Table S7. Multivariable-Adjusted Hazard Ratios for Secondary Endpoints in Relation to Hypertension Categories by 24-H BP**

Characteristic	CV Mortality (n=1073)		Cardiac Event (n=1359)		Coronary Event (n=922)		Stroke (n=822)	
	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P
<b>AHA/ACC 2017 criteria</b>								
Normotensive (n=5418)	Reference		Reference		Reference		Reference	
Isolated Diastolic (n=1129)	0.99 (0.72–1.36)	0.96	1.14 (0.90–1.45)	0.28	1.07 (0.80–1.42)	0.66	1.10 (0.77–1.56)	0.60
Isolated Systolic (n=1325)	1.39 (1.17–1.65)	<0.001	1.36 (1.16–1.60)	<0.001	1.48 (1.22–1.80)	<0.001	1.40 (1.14–1.72)	0.001
Combined (n=3263)	1.69 (1.45–1.97)	<0.001	1.64 (1.43–1.87)	<0.001	1.60 (1.35–1.88)	<0.001	1.88 (1.58–2.23)	<0.001
<b>ESC 2018 criteria</b>								
Normotensive (n=7391)	Reference		Reference		Reference		Reference	
Isolated Diastolic (n=574)	1.57 (1.07–2.30)	0.020	1.66 (1.26–2.18)	<0.001	1.57 (1.13–2.16)	0.007	1.07 (0.65–1.78)	0.78
Isolated Systolic (n=1429)	1.64 (1.41–1.91)	<0.001	1.45 (1.26–1.67)	<0.001	1.60 (1.35–1.89)	<0.001	1.75 (1.47–2.08)	<0.001
Combined (n=1741)	1.97 (1.69–2.30)	<0.001	1.73 (1.50–1.98)	<0.001	1.69 (1.43–2.01)	<0.001	2.01 (1.68–2.39)	<0.001

Abbreviations: BP, blood pressure; CI, 95% confidence interval; CV, cardiovascular; HR, Hazard ratio. The 24-h systolic/diastolic BP thresholds were 125/75 mm Hg by AHA/ACC 2017 and 130/80 mm Hg by ESC 2018. Normotension refers to those with both systolic/diastolic BPs were lower than the cut-off values, while combined hypertension refers to those with both systolic/diastolic BPs were equal to or higher than the cut-off values. Isolated systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. HRs express the relative risk compared with the normotensive group as reference and were adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, antihypertensive drug intake, history of cardiovascular disease and diabetes mellitus.

**Table S8. Multivariable-Adjusted Hazard Ratios for Secondary Endpoints in Relation to Hypertension Categories by Nighttime BP**

Characteristic	CV Mortality (n=1073)		Cardiac Event (n=1359)		Coronary Event (n=922)		Stroke (n=822)	
	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P
<b>AHA/ACC 2017 criteria</b>								
Normotensive (n=4766)	Reference		Reference		Reference		Reference	
Isolated Diastolic (n=772)	0.91 (0.63–1.30)	0.59	1.13 (0.86–1.49)	0.37	1.11 (0.81–1.53)	0.52	1.26 (0.87–1.84)	0.23
Isolated Systolic (n=1542)	1.27 (1.06–1.53)	0.010	1.36 (1.15–1.61)	<0.001	1.34 (1.09–1.64)	0.005	1.41 (1.14–1.76)	0.002
Combined (n=4055)	1.51 (1.29–1.75)	<0.001	1.56 (1.36–1.78)	<0.001	1.52 (1.29–1.80)	<0.001	1.85 (1.55–2.20)	<0.001
<b>ESC 2018 criteria</b>								
Normotensive (n=7362)	Reference		Reference		Reference		Reference	
Isolated Diastolic (n=834)	1.07 (0.80–1.44)	0.65	1.28 (1.03–1.60)	0.030	1.24 (0.95–1.63)	0.11	0.91 (0.64–1.29)	0.58
Isolated Systolic (n=979)	1.53 (1.29–1.81)	<0.001	1.52 (1.30–1.78)	<0.001	1.56 (1.29–1.89)	<0.001	1.45 (1.18–1.77)	<0.001
Combined (n=1960)	1.86 (1.61–2.15)	<0.001	1.71 (1.50–1.95)	<0.001	1.70 (1.45–2.00)	<0.001	1.81 (1.53–2.13)	<0.001

Abbreviations: BP, blood pressure; CI, 95% confidence interval; CV, cardiovascular; HR, Hazard ratio. The nighttime systolic/diastolic BP thresholds were 110/65 mm Hg by AHA/ACC 2017 and 120/70 mm Hg by ESC 2018. Normotension refers to those with both systolic/diastolic BPs were lower than the cut-off values, while combined hypertension refers to those with both systolic/diastolic BPs were equal to or higher than the cut-off levels. Isolated systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. HRs express the relative risk compared with the normotensive group as reference and were adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, antihypertensive drug intake, history of cardiovascular disease and diabetes mellitus.

**Table S9. Multivariable-Adjusted Hazard Ratio in Relation to Hypertension Categories by 24-H BP Among 9844 Participants without History of Cardiovascular Disease at Baseline**

Characteristic	Total Mortality (n=2283)		CV Event (n=1589)	
	HR (95%CI)	P value	HR (95%CI)	P value
<b>2017 AHA/ACC Criteria</b>				
Normotensive (n=4966)	Reference		Reference	
Isolated Diastolic (n=1015)	0.98 (0.80–1.20)	0.85	1.22 (0.97–1.53)	0.086
Isolated Systolic (n=1072)	1.14 (1.01–1.29)	0.036	1.34 (1.16–1.56)	<0.001
Combined (n=2791)	1.36 (1.23–1.51)	<0.001	1.81 (1.60–2.05)	<0.001
<b>2018 ESC Criteria</b>				
Normotensive (n=6711)	Reference		Reference	
Isolated Diastolic (n=509)	1.30 (1.00–1.70)	0.054	1.54 (1.17–2.03)	0.002
Isolated Systolic (n=1155)	1.38 (1.24–1.54)	<0.001	1.59 (1.39–1.81)	<0.001
Combined (n=1469)	1.41 (1.26–1.57)	<0.001	1.97 (1.73–2.23)	<0.001

Abbreviations: BP, blood pressure; CI, 95% confidence interval; CV, cardiovascular; HR, Hazard ratio. The 24-h systolic/diastolic BP thresholds were 125/75 mm Hg by 2017 AHA/ACC and 130/80 mm Hg by 2018 ESC definitions. Normotension refers to those with both systolic/diastolic BPs were lower than the cut-off values, while combined hypertension refers to those with both systolic/diastolic BPs were equal to or higher than the cut-off values. Isolated systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. HRs express the relative risk compared with the normotensive group as reference and were adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, antihypertensive drug intake, and history of diabetes mellitus.

**Table S10. Multivariable-Adjusted Hazard Ratio in Relation to Hypertension Categories by Nighttime BP Among 9844 Participants without History of Cardiovascular Disease at Baseline**

Characteristic	Total Mortality (n=2283)		CV Event (n=1589)	
	HR (95%CI)	P value	HR (95%CI)	P value
<b>2017 AHA/ACC Criteria</b>				
Normotensive (n=4397)	Reference		Reference	
Isolated Diastolic (n=701)	1.02 (0.82–1.27)	0.84	1.08 (0.83–1.41)	0.56
Isolated Systolic (n=1320)	1.15 (1.01–1.30)	0.034	1.30 (1.11–1.52)	0.001
Combined (n=3426)	1.29 (1.16–1.42)	<0.001	1.65 (1.46–1.86)	<0.001
<b>2018 ESC Criteria</b>				
Normotensive (n=6724)	Reference		Reference	
Isolated Diastolic (n=736)	1.16 (0.97–1.40)	0.11	1.17 (0.94–1.46)	0.15
Isolated Systolic (n=795)	1.32 (1.16–1.49)	<0.001	1.45 (1.25–1.68)	<0.001
Combined (n=1589)	1.42 (1.28–1.57)	<0.001	1.79 (1.59–2.02)	<0.001

Abbreviations: BP, blood pressure; CI, 95% confidence interval; CV, cardiovascular; HR, Hazard ratio. The nighttime systolic/diastolic BP thresholds were 110/65 mm Hg by 2017 AHA/ACC and 120/70 mm Hg by 2018 ESC definitions. Normotension refers to those with both systolic/diastolic BPs were lower than the cut-off values, while combined hypertension refers to those with both systolic/diastolic BPs were equal to or higher than the cut-off values. Isolated systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. HRs express the relative risk compared with the normotensive group as reference and were adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, antihypertensive drug intake, and history of diabetes mellitus.



**Table S11. Number of Participants and Events by 24-H Hypertension Category by AHA/ACC 2017 or ESC 2018 Criteria and Age Strata**

Hypertension category	Total mortality (n/N, per 1000 person-years)		Cardiovascular events (n/N, per 1000 person-years)	
	Age<50	Age≥50	Age<50	Age≥50
<b>AHA/ACC 2017 criteria</b>				
Normotensive	59/2796, 1.47	888/2622, 23.0	43/2796, 1.08	555/2622, 15.2
Isolated diastolic	18/547, 2.65	120/582, 16.0	25/547, 3.71	91/582, 12.9
Isolated systolic	3/211, 0.92	592/1114, 41.8	3/211, 0.92	420/1114, 32.7
Combined	40/698, 3.96	1116/2565, 34.4	37/698, 3.74	875/2565, 30.3
<b>ESC 2018 criteria</b>				
Normotensive	83/3528, 1.64	1331/3863, 23.8	68/3528, 1.35	857/3863, 16.4
Isolated diastolic	10/263, 3.21	60/311, 17.1	13/263, 4.21	56/311, 17.0
Isolated systolic	5/163, 1.89	714/1266, 46.0	7/163, 2.70	505/1266, 36.9
Combined	22/298, 5.34	611/1443, 34.2	20/298, 4.99	523/1443, 33.0

The 24-h systolic/diastolic BP thresholds were 125/75 mm Hg by AHA/ACC 2017 or 130/80 mm Hg by ESC 2018 guidelines.

**Table S12. Number of Participants and Events by 24-H Hypertension Category by AHA/ACC 2017 or ESC 2018 Criteria and Gender**

Hypertension Category	Total Mortality (n/N, per 1000 Person-Years)		Cardiovascular Events (n/N, per 1000 Person-Years)	
	Male	Female	Male	Female
<b>AHA/ACC 2017 Criteria</b>				
Normotensive	592/2179, 19.4	355/3239, 7.36	371/2179, 12.8	227/3239, 4.80
Isolated diastolic	96/644, 11.5	42/485, 7.05	84/644, 10.6	32/485, 5.49
Isolated systolic	382/726, 38.8	213/599, 28.0	265/729, 29.8	158/599, 22.0
Combined	879/2092, 32.2	277/1171, 18.2	694/2092, 28.4	218/1171, 15.2
<b>ESC 2018 Criteria</b>				
Normotensive	917/3329, 19.6	497/4062, 8.34	594/3329, 13.4	331/4062, 5.69
Isolated diastolic	51/339, 12.9	19/235, 7.09	52/339, 13.9	17/235, 6.45
Isolated systolic	490/823, 45.5	229/606, 30.9	345/823, 36.7	167/606, 24.3
Combined	491/1150, 33.7	142/591, 19.2	423/1150, 32.8	120/591, 17.2

The 24-h systolic/diastolic BP thresholds were 125/75 mm Hg by AHA/ACC 2017 or 130/80 mm Hg by ESC 2018 guidelines.

**Table S13. Hazard Ratio by 24-H Hypertension Category by AHA 2017 and ESC 2018 Definition Stratified by Gender**

Characteristic	Total Mortality					CV Events				
	Male		Female		$P_{int}$	Male		Female		$P_{int}$
	HR (95%CI)	<i>P</i>	HR (95%CI)	<i>P</i>		HR (95%CI)	<i>P</i>	HR (95%CI)	<i>P</i>	
<b>2017 AHA/ACC criteria</b>										
Normotensive	Reference		Reference			Reference		Reference		
Isolated Diastolic	0.85 (0.69–1.06)	0.16	1.16 (0.84–1.61)	0.36	0.16	1.08 (0.85–1.37)	0.55	1.25 (0.86–1.82)	0.24	0.73
Isolated Systolic	1.06 (0.93–1.21)	0.40	1.36 (1.13–1.63)	0.001	0.039	1.21 (1.03–1.43)	0.020	1.60 (1.28–1.98)	<0.001	0.037
Combined	1.29 (1.15–1.44)	<0.001	1.43 (1.22–1.69)	<0.001	0.42	1.67 (1.46–1.91)	<0.001	1.78 (1.47–2.17)	<0.001	0.78
<b>ESC 2018 criteria</b>										
Normotensive	Reference		Reference			Reference		Reference		
Isolated Diastolic	1.09 (0.82–1.45)	0.55	1.70 (1.06–2.73)	0.026	0.097	1.38 (1.03–1.83)	0.030	1.61 (0.98–2.64)	0.063	0.86
Isolated Systolic	1.29 (1.15–1.44)	<0.001	1.53 (1.30–1.81)	<0.001	0.092	1.45 (1.26–1.67)	<0.001	1.69 (1.39–2.06)	<0.001	0.18
Combined	1.32 (1.18–1.48)	<0.001	1.51 (1.24–1.82)	<0.001	0.33	1.84 (1.61–2.10)	<0.001	1.81 (1.46–2.25)	<0.001	0.81

Abbreviations: BP, blood pressure; CI, 95% confidence interval; CV, cardiovascular; HR, Hazard ratio. The 24-h systolic/diastolic BP thresholds were 125/75 mm Hg by 2017 AHA/ACC and 130/80 mm Hg by 2018 ESC definitions. Normotension refers to those with both systolic/diastolic BPs were lower than the cut-off values, while combined hypertension refers to those with both systolic/diastolic BPs were equal to or higher than the cut-off levels. Isolated systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. HRs express the relative risk compared with the normotensive group in the age stratification as reference and were adjusted for cohort (random effect), age, body mass index, smoking and drinking, serum total cholesterol, antihypertensive drug intake, history of cardiovascular disease and diabetes.  $P_{int}$  is for the interaction between hypertension classifications and different genders.